Lupin launches drug for Asthma patient

Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US

76

Last Updated on August 26, 2021 by The Health Master

Following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, Lupin Healthcare has launched Luforbec (beclometasone / formoterol) 100/6 dose pressurised metered dose inhaler (pMDI).

It is available now to patients in the UK, with the potential to offer significant cost savings for the NHS, the company said in a statement.

Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50 per cent predicted normal).

Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US, added the statement.

Merck launches Pergoveris Pen for Infertility treatment in India

Alkem launches Ibuprofen, Famotidine tablets

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Latest Notifications regarding Pharmaceuticals

Proposed Pharma cluster: Rs 400 crore investment

Pfizer becomes first Covid vaccine globally to get full USFDA approval

3 Labs booked for Prenatal testing without permission

J&J submits application to CDSCO for study of Covid-19 vaccine on…

High court denied bail in Drug seizure case

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner